JP2023517920A5 - - Google Patents
Info
- Publication number
- JP2023517920A5 JP2023517920A5 JP2022554382A JP2022554382A JP2023517920A5 JP 2023517920 A5 JP2023517920 A5 JP 2023517920A5 JP 2022554382 A JP2022554382 A JP 2022554382A JP 2022554382 A JP2022554382 A JP 2022554382A JP 2023517920 A5 JP2023517920 A5 JP 2023517920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- dosage form
- product according
- oral administration
- unit dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987429P | 2020-03-10 | 2020-03-10 | |
| US62/987,429 | 2020-03-10 | ||
| US202063003601P | 2020-04-01 | 2020-04-01 | |
| US63/003,601 | 2020-04-01 | ||
| US202063034817P | 2020-06-04 | 2020-06-04 | |
| US63/034,817 | 2020-06-04 | ||
| US202063074799P | 2020-09-04 | 2020-09-04 | |
| US63/074,799 | 2020-09-04 | ||
| US202063125427P | 2020-12-15 | 2020-12-15 | |
| US63/125,427 | 2020-12-15 | ||
| PCT/IB2021/000131 WO2021181157A1 (en) | 2020-03-10 | 2021-03-08 | Treatment of coronavirus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517920A JP2023517920A (ja) | 2023-04-27 |
| JP2023517920A5 true JP2023517920A5 (https=) | 2024-02-01 |
| JP7822946B2 JP7822946B2 (ja) | 2026-03-03 |
Family
ID=76548186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554382A Active JP7822946B2 (ja) | 2020-03-10 | 2021-03-08 | コロナウイルス感染の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US11052073B1 (https=) |
| EP (1) | EP4117630A4 (https=) |
| JP (1) | JP7822946B2 (https=) |
| KR (1) | KR20220151613A (https=) |
| CN (2) | CN117695284B (https=) |
| AU (1) | AU2021235304A1 (https=) |
| BR (1) | BR112022017923A2 (https=) |
| CA (1) | CA3174438A1 (https=) |
| IL (1) | IL295658A (https=) |
| MX (1) | MX2022011173A (https=) |
| WO (1) | WO2021181157A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| CN117695284B (zh) | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| US11471448B2 (en) * | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN113398219A (zh) * | 2021-06-30 | 2021-09-17 | 广州白云山星群(药业)股份有限公司 | 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途 |
| EP4286851A1 (en) | 2022-06-01 | 2023-12-06 | Universität Wien | Methods and means for molecular characterization of post-viral fatigue syndrome |
| WO2025133697A2 (en) * | 2023-12-20 | 2025-06-26 | Redhill Biopharma Ltd. | Combination therapy for inhibition of ebolavirus |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| US6624169B1 (en) | 1998-07-20 | 2003-09-23 | Wilex Biotechnology Gmbh | Urokinase inhibitors |
| AU9059798A (en) | 1998-09-18 | 2000-04-10 | Pentapharm Ag | Urokinase inhibitors |
| DE50211672D1 (de) | 2001-03-21 | 2008-03-27 | Wilex Ag | Urokinase-inhibitoren |
| CH695999A5 (de) | 2002-02-28 | 2006-11-15 | Wilex Ag | Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten. |
| WO2004011449A2 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur herstellung von phenylalanin-derivaten |
| DE10238048A1 (de) | 2002-07-25 | 2004-02-05 | Wilex Ag | Verfahren zur Herstellung von Phenylalanin-Derivaten |
| US9770349B2 (en) * | 2002-11-13 | 2017-09-26 | University Of Virginia Patent Foundation | Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation |
| DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| RU2234313C1 (ru) | 2003-06-04 | 2004-08-20 | Кривошеин Юрий Семенович | Средство инактивации коронавирусов |
| GB0420874D0 (en) | 2004-09-20 | 2004-10-20 | Swetree Technologies Ab | Modulation of flowering time and growth cessation in perennial plants |
| DE102004045720A1 (de) | 2004-09-21 | 2006-03-23 | Wilex Ag | Stabile Dosierungsform von Phenylalanin-Derivaten |
| BRPI0516106B1 (pt) | 2004-10-14 | 2021-08-24 | Wilex Ag | Métodos para purificação e preparação de derivados de 3-hidroxiamidinofenilalanina, e para produção de derivados de 3-amidinofenilalanina |
| DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| ES2528451T3 (es) | 2005-06-17 | 2015-02-10 | Apogee Biothechnology Corporation | Inhibidores de esfingosina cinasa |
| WO2012166859A2 (en) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| CA2965258C (en) * | 2014-10-24 | 2023-09-19 | Redhill Biopharma Ltd. | Therapy for inhibition of single-stranded rna virus replication |
| DK3297438T3 (da) * | 2015-05-21 | 2022-01-17 | Chemocentryx Inc | Ccr2-modulatorer |
| WO2017060771A2 (en) * | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| US10195188B2 (en) * | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| US10251888B2 (en) * | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| CN117695284B (zh) * | 2020-03-10 | 2025-06-17 | 红山生物医药有限公司 | 冠状病毒感染的治疗 |
| EP4126234A1 (en) | 2020-04-02 | 2023-02-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Compositions for coronavirus infection treatment and/or prevention |
-
2021
- 2021-03-08 CN CN202311591091.6A patent/CN117695284B/zh active Active
- 2021-03-08 JP JP2022554382A patent/JP7822946B2/ja active Active
- 2021-03-08 US US17/195,279 patent/US11052073B1/en active Active
- 2021-03-08 KR KR1020227029182A patent/KR20220151613A/ko active Pending
- 2021-03-08 BR BR112022017923A patent/BR112022017923A2/pt unknown
- 2021-03-08 EP EP21768527.0A patent/EP4117630A4/en active Pending
- 2021-03-08 CA CA3174438A patent/CA3174438A1/en active Pending
- 2021-03-08 CN CN202180022144.5A patent/CN115515560B/zh active Active
- 2021-03-08 AU AU2021235304A patent/AU2021235304A1/en active Pending
- 2021-03-08 WO PCT/IB2021/000131 patent/WO2021181157A1/en not_active Ceased
- 2021-03-08 MX MX2022011173A patent/MX2022011173A/es unknown
- 2021-03-08 US US17/195,333 patent/US11045453B1/en active Active
- 2021-03-08 IL IL295658A patent/IL295658A/en unknown
- 2021-06-10 US US17/344,430 patent/US11918560B2/en active Active
- 2021-06-30 US US17/364,386 patent/US12551469B2/en active Active
- 2021-10-15 US US17/502,932 patent/US11364227B2/en active Active
-
2024
- 2024-01-30 US US18/426,914 patent/US12502381B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517920A5 (https=) | ||
| ES2313797T7 (es) | Composición de liberación modificada multiparticulada de fenidato de metilo | |
| ES2320438T7 (es) | Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s) | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| JP2005515966A5 (https=) | ||
| CY1118946T1 (el) | Μορφοποιησεις μεθυλφαινυδατης ελεγχομενης αποδεσμευσης | |
| CN1188130C (zh) | 夸噻平颗粒 | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| RU2004139088A (ru) | Препарат ламотриджин с контролируемым высвобождением | |
| TW303367B (https=) | ||
| JPH04500070A (ja) | アスピリンの新規投与方法およびアスピリンを含有する新規剤形 | |
| JP2023541766A5 (https=) | ||
| ES2207858T3 (es) | Composicion farmaceutica activa para reducir la produccion de proteina mcp-1". | |
| JP2009502951A5 (https=) | ||
| HRP20090679T1 (hr) | Upotreba oksikodona za liječenje organske boli | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| ES2194618T3 (es) | Nueva formulacion de mirtazapina. | |
| JP2025517509A5 (https=) | ||
| JP2024500632A5 (https=) | ||
| JP2006524190A5 (https=) | ||
| CN109922795A (zh) | 褪黑素小片剂及其制备方法 | |
| JPH09500121A (ja) | 痴呆症の治療のためのナブメトンまたは６−メトキシナフチル酢酸の使用 | |
| EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
| RU2003100081A (ru) | Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии |